Kawagoe K, Tsunoda H, Iijima S, Yokota H, Shigemitsu S
Gan To Kagaku Ryoho. 1984 Mar;11(3):452-7.
In 23 cases of gynecological malignancies, comparative analysis of the side effects of a combination chemotherapy of cisplatinum (CDDP) and adriamycin (ADM) was performed in terms of administration routes: intravenous and intraarterial. 50 mg/m2 of CDDP and 50 mg/m2 of ADM were administered intravenously once for three weeks. 12.5 mg of CDDP and 10 mg of ADM per one catheter were infused intraarterially once or twice a week. More than severe leukocytopenia was observed in all cases of systemic administration, while in 25% of intraarterial infusion. In 90% of intravenous administration and in about a half of intraarterial cases, thrombocytopenia was noted. Myelosuppression was severest at 10 the to 12th day after administration. The value of creatinine clearance (C-Cr) was within normal limits in 10% of cases of intravenous and in nearly 50% of cases of intraarterial administration. No mortal cases due to myelosuppression and no renal failure ware observed. Most cases of intravenous administration were suffered from severe vomiting, while only in half cases of intraarterial chemotherapy milder emesis appeared. Antiemetic drugs should be administered at least for one week after systemic chemotherapy, and also intraarterial chemotherapy, if necessary.
对23例妇科恶性肿瘤患者，就顺铂（CDDP）和阿霉素（ADM）联合化疗通过静脉和动脉两种给药途径的副作用进行了对比分析。静脉给药时，每三周一次给予50mg/m²的CDDP和50mg/m²的ADM。动脉给药时，每根导管每次注入12.5mg的CDDP和10mg的ADM，每周一次或两次。全身给药的所有病例均出现了严重白细胞减少，而动脉内灌注病例中该情况占25%。90%的静脉给药病例和大约一半的动脉给药病例出现了血小板减少。骨髓抑制在给药后第10至12天最为严重。静脉给药病例中有10%、动脉给药病例中有近50%的肌酐清除率（C-Cr）值在正常范围内。未观察到因骨髓抑制导致的死亡病例和肾衰竭病例。大多数静脉给药病例出现严重呕吐，而动脉内化疗只有半数病例出现较轻呕吐。全身化疗后至少应使用止吐药一周，必要时动脉内化疗也应如此。
